The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors

Lauren L Campbell Marotta(Harvard University Press), Kornélia Polyák(Dana-Farber Cancer Institute), Andrea L. Richardson(Johns Hopkins University), Vanessa Almendro(Danaher (United States)), Karen S. Anderson(Institute for Biodiversity), Serena J. Silver(Broad Institute), X. Shirley Liu(Harbin Medical University), David A. Frank(Brigham and Women's Hospital), Mithat Gönen(Memorial Sloan Kettering Cancer Center), Reo Maruyama(Harvard University Press), William C. Hahn(Broad Institute), Laura Mulvey(Dana-Farber Cancer Institute), Yuri Nikolsky(Johns Hopkins University), Hee Eun Lee(Seoul National University), Michail Shipitsin(C4 Therapeutics (United States)), Janina Schemme(Dana-Farber Cancer Institute), Sarah R. Walker(Harvard University Press), David E. Root(Broad Institute), So Young Kim(Chungbuk National University), Zhenhua Wu(Zhejiang Chinese Medical University), So Yeon Park(Seoul National University Bundang Hospital), Sung Jin Huh(Harvard University Press), Sibgat Choudhury(Harvard University Press), Jessica Kim(Harvard University Press), Noga Bloushtain-Qimron(Dana-Farber Cancer Institute), Tatiana Nikolskaya(Russian Academy of Sciences), Andriy Marusyk(Moffitt Cancer Center)
Journal of Clinical Investigation
June 1, 2011
Cited by 928


Related Papers